Late Initiation of HAART Among HIV-Infected Patients in Spain Is Frequent and Related to a Higher Rate of Virological Failure but not to Immigrant Status

Management of late-presenting patients with HIV infection

(2010) Jurgen K Rockstroh et al.   ANTIVIRAL THERAPY

Definition and epidemiology of late presentation in Europe

(2010) Margaret Johnson et al.   ANTIVIRAL THERAPY

Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study

(2010) Jose A. Perez-Molina et al.   CURRENT HIV RESEARCH

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Delayed Diagnosis of HIV Infection in a Multicenter Cohort: Prevalence, Risk Factors, Response to HAART and Impact on Mortality

(2009) Paz Sobrino-Vegas et al.   CURRENT HIV RESEARCH

British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naïve

(2009) E Street et al.   HIV MEDICINE

Ethnicity, Race, and Gender

(2009) Ellen M Tedaldi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

(2009) Paul E. Sax et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996–2008)

(2009) Jorge L Martinez-Cajas et al.   Journal of the International AIDS Society

Patients presenting with AIDS in the HAART era: a collaborative cohort analysis

(2008) Cristina Mussini et al.   AIDS

Barriers to HIV testing for migrant black Africans in Western Europe

(2008) I Fakoya et al.   HIV MEDICINE

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

(2008) BG Gazzard et al.   HIV MEDICINE

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET

Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people

(2007) C. Delpierre et al.   EUROPEAN JOURNAL OF PUBLIC HEALTH